ACHFF
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.01 | $0 | -$89,338 |
| 2025 Q1 | -0.02 | $0 | -$849,246 |
| 2025 Q4 | -0.00 | $0 | -$257,900 |
| 2025 Q3 | -0.00 | $158,079 | $113,717 |
| 2025 Q2 | -0.01 | $0 | -$574,641 |
| 2024 Q1 | -0.01 | $117,865 | -$903,055 |
| 2024 Q4 | -0.02 | -$361,000 | -$469,844 |
| 2024 Q3 | -0.01 | $855 | -$864,113 |